콘텐츠로 건너뛰기
Merck
모든 사진(3)

Key Documents

추가 자료

F6777

Sigma-Aldrich

Flecainide acetate salt

≥98% (TLC), powder, sodium channel blocker

동의어(들):

N-(2-Piperidylmethyl)-2,5-bis-(2,2,2-trifluoroethoxy)benzamide acetate salt

로그인조직 및 계약 가격 보기
모든 사진(3)

About This Item

실험식(Hill 표기법):
C17H20F6N2O3 · C2H4O2
CAS Number:
54143-56-5
Molecular Weight:
474.39
EC Number:
258-997-5
MDL number:
MFCD00214290
UNSPSC 코드:
12352200
PubChem Substance ID:
24278440
NACRES:
NA.77

product name

Flecainide acetate salt,

Quality Level

200

주관자

Medicis

저장 온도

2-8°C

SMILES string

CC(O)=O.FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC2CCCCN2

InChI

1S/C17H20F6N2O3.C2H4O2/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11;1-2(3)4/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26);1H3,(H,3,4)

InChI key

RKXNZRPQSOPPRN-UHFFFAOYSA-N

유전자 정보

human ... SCN5A(6331)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

생화학적/생리학적 작용

Class IC antiarrhythmic agent; sodium channel blocker

특징 및 장점

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Medicis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

픽토그램

Health hazardExclamation mark
GHS08,GHS07

신호어

Danger

유해 및 위험 성명서

H302,H315,H319,H335,H360FD

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2 - STOT SE 3

표적 기관

Respiratory system

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Drug therapy. Flecainide.
D M Roden et al.
The New England journal of medicine, 315(1), 36-41 (1986-07-03)
P Somani
Clinical pharmacology and therapeutics, 27(4), 464-470 (1980-04-01)
A new class I antiarrhythmic, flecainide, was investigated in 10 patients to assess short-term efficacy and safety. All patients were hospitalized for 3 days; no antiarrhythmics were given on days 1 and 3. On day 2 flecainide 1 mg/kg was
Naomasa Makita et al.
The Journal of clinical investigation, 118(6), 2219-2229 (2008-05-03)
Phenotypic overlap of type 3 long QT syndrome (LQT3) with Brugada syndrome (BrS) is observed in some carriers of mutations in the Na channel SCN5A. While this overlap is important for patient management, the clinical features, prevalence, and mechanisms underlying
Kosuke Doki et al.
Pharmacogenetics and genomics, 22(11), 777-783 (2012-09-04)
To investigate the association between age-related decline in flecainide clearance and CYP2D6 genotype, we conducted a population pharmacokinetic analysis of flecainide using routine therapeutic drug monitoring data. Population pharmacokinetic analysis was performed on retrospective data from 163 genotyped patients treated
Nian Liu et al.
Trends in cardiovascular medicine, 22(2), 35-39 (2012-08-08)
Recent studies have shown that flecainide may be an effective therapy to prevent life-threatening arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. Several hypotheses have been advanced to explain the antiarrhythmic mechanism of flecainide, including Na(+) channel blockade and a
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.